TY - JOUR
T1 - Serum calprotectin as a biomarker for Crohn's disease
AU - Meuwis, M. A.
AU - Vernier-Massouille, G.
AU - Grimaud, J. C.
AU - Bouhnik, Y.
AU - Laharie, D.
AU - Piver, E.
AU - Seidel, L.
AU - Colombel, J. F.
AU - Louis, E.
N1 - Funding Information:
Financial support for the STORI trial was provided by the SNFGE and the association François Aupetit . We thank S Adriaens for technical assistance. The following GETAID Centers (investigators) participated in this study: Amiens (J. L. Dupas), Bordeaux (D. Laharie), Caen (J. M. Reimund), Clichy-Beaujon (Y. Bouhnik), Colombes-L Mourier (P. Jouet), Gent (M. De Vos), Liège (J. Belaiche, E. Louis), Lille (J.-F. Colombel, G. Vernier-Massouille), Lyon (S. Nancey), Marseille (J. C. Grimaud), Montpellier (M.Veyrac), Nantes (A. Boureille, M. Flamant), Paris-HEGP (R. Jian), Paris-Lariboisière (P. Marteau), Paris-St Louis (M. Lemann, M. Allez), Rouen (G. Savoye), Strasbourg (B. Duclos), and Tours (L. Picon).
PY - 2013/12/15
Y1 - 2013/12/15
N2 - Background and aims: In Crohn's disease, correlation between clinical assessment and disease activity at tissue level is weak. Our aim was to evaluate the value of serum calprotectin as a biomarker for Crohn's disease. Methods: The STORI trial patients (n. = 115) were studied at baseline, in clinical remission before infliximab withdrawal, or at the time of relapse after infliximab withdrawal. Forty healthy controls were also studied. Serum calprotectin level was measured by ELISA. Data were analyzed through correlation analyses, Kaplan Meier curves and Cox model, using available Crohn's Disease Activity Index (CDAI), Crohn's Disease Endoscopic Index of Severity (CDEIS), fecal calprotectin and C-reactive protein levels (hsCRP). Results: Median serum calprotectin was 8892. ng/mL (range: 410-125,000. ng/mL) in Crohn disease patients as compared with 1318. ng/mL (range: 215.8-3770. ng/mL) in controls (P<. 0.0001). Serum calprotectin was significantly higher for active disease (median. = 19,584. ng/mL) than for inactive disease (median. = 8353. ng/mL) (P<. 0.0001). Serum calprotectin correlated with hsCRP (r. = 0.4092, P<. 0.0001) and CDAI (r. = 0.4442, P<. 0.0001), but not with CDEIS, on the contrary to fecal calprotectin (r. = 0.6458, 0.5515, 0.2577 with P<. 0.0001, P<. 0.0001, P= 0.019 respectively). In multivariate analysis, serum calprotectin used as a discrete variable (threshold: 5675. ng/ml), appeared complementary to hsCRP (>. 5. mg/l) and fecal calprotectin (>. 250. μg/g) to predict relapse after infliximab withdrawal (P= 0.0173, 0.0024 and 0.0002; HR: 3.191, 3.561 and 4.120). Conclusions: As a CD biomarker, serum calprotectin has a similar profile as hsCRP. It is also complementary to fecal calprotectin and hsCRP for prediction of relapse after infliximab withdrawal.
AB - Background and aims: In Crohn's disease, correlation between clinical assessment and disease activity at tissue level is weak. Our aim was to evaluate the value of serum calprotectin as a biomarker for Crohn's disease. Methods: The STORI trial patients (n. = 115) were studied at baseline, in clinical remission before infliximab withdrawal, or at the time of relapse after infliximab withdrawal. Forty healthy controls were also studied. Serum calprotectin level was measured by ELISA. Data were analyzed through correlation analyses, Kaplan Meier curves and Cox model, using available Crohn's Disease Activity Index (CDAI), Crohn's Disease Endoscopic Index of Severity (CDEIS), fecal calprotectin and C-reactive protein levels (hsCRP). Results: Median serum calprotectin was 8892. ng/mL (range: 410-125,000. ng/mL) in Crohn disease patients as compared with 1318. ng/mL (range: 215.8-3770. ng/mL) in controls (P<. 0.0001). Serum calprotectin was significantly higher for active disease (median. = 19,584. ng/mL) than for inactive disease (median. = 8353. ng/mL) (P<. 0.0001). Serum calprotectin correlated with hsCRP (r. = 0.4092, P<. 0.0001) and CDAI (r. = 0.4442, P<. 0.0001), but not with CDEIS, on the contrary to fecal calprotectin (r. = 0.6458, 0.5515, 0.2577 with P<. 0.0001, P<. 0.0001, P= 0.019 respectively). In multivariate analysis, serum calprotectin used as a discrete variable (threshold: 5675. ng/ml), appeared complementary to hsCRP (>. 5. mg/l) and fecal calprotectin (>. 250. μg/g) to predict relapse after infliximab withdrawal (P= 0.0173, 0.0024 and 0.0002; HR: 3.191, 3.561 and 4.120). Conclusions: As a CD biomarker, serum calprotectin has a similar profile as hsCRP. It is also complementary to fecal calprotectin and hsCRP for prediction of relapse after infliximab withdrawal.
KW - Biomarker
KW - Crohn's disease
KW - Infliximab
KW - Relapse prediction
KW - Serum calprotectin
UR - http://www.scopus.com/inward/record.url?scp=84887609133&partnerID=8YFLogxK
U2 - 10.1016/j.crohns.2013.06.008
DO - 10.1016/j.crohns.2013.06.008
M3 - Article
C2 - 23845231
AN - SCOPUS:84887609133
SN - 1873-9946
VL - 7
SP - e678-e683
JO - Journal of Crohn's and Colitis
JF - Journal of Crohn's and Colitis
IS - 12
ER -